Pfizer's BRAFTOVI combo cut death risk by 51% and more than doubled survival in BRAF-mutant colorectal cancer in a Phase 3 ...

Phase III progression-free survival data were positive for first-line Braftovi in first-line combination therapy for mCRC.

Pfizer (PFE) stock gains as Braftovi combo shows survival benefits in a late-stage trial for metastatic colorectal cancer ...

Adding Pfizer’s BRAF inhibitor Braftovi to a cocktail of cancer drugs cut the risk of death for certain colorectal cancer ...

The BREAKWATER trial showed improved response rates and survival with Braftovi, Erbitux, and chemotherapy in BRAF V600E-mutated metastatic colorectal cancer. FDA approval in December 2024 highlights ...

The randomized multicenter trial examined the combination of encorafenib (Braftovi, Pfizer) and cetuximab (Erbitux, Imclone) in the front-line setting with chemotherapy for the treatment of BRAF ...

Pfizer Inc. announced positive topline results from the progression-free survival (PFS) analysis of the phase 3 BREAKWATER study of Braftovi (encorafenib) in combination with cetuximab (marketed as ...

The BREAKWATER trial, a randomized, active-controlled, open-label, multicenter study, compared the efficacy of BRAFTOVI with cetuximab and mFOLFOX6 against standard chemotherapy with or without ...

At the time of the ORR analysis, the safety profile of BRAFTOVI in combination with cetuximab and mFOLFOX6 continued to be consistent with the known safety profile of each respective agent.